These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 24293573)
21. A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors. Walters HM; Pan N; Lehman TJ; Adams A; Huang WT; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS Clin Rheumatol; 2015 Mar; 34(3):457-64. PubMed ID: 25227771 [TBL] [Abstract][Full Text] [Related]
22. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Beukelman T; Xie F; Chen L; Baddley JW; Delzell E; Grijalva CG; Lewis JD; Ouellet-Hellstrom R; Patkar NM; Saag KG; Winthrop KL; Curtis JR; Arthritis Rheum; 2012 Aug; 64(8):2773-80. PubMed ID: 22569881 [TBL] [Abstract][Full Text] [Related]
23. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Cimaz R; Cazalis MA; Reynaud C; Gerloni V; Zulian F; Biggioggero M; Martini G; Pontikaki I; Fantini F; Mougin B; Miossec P Ann Rheum Dis; 2007 Jul; 66(7):900-4. PubMed ID: 17324969 [TBL] [Abstract][Full Text] [Related]
24. Growth and body mass index in a cohort of patients with juvenile idiopathic arthritis: effects of second line treatments. Marino A; Stagi S; Simonini G; Carli N; Caparello MC; Giani T; Pagnini I; De Masi S; Cimaz R Clin Exp Rheumatol; 2018; 36(5):929-933. PubMed ID: 30148444 [TBL] [Abstract][Full Text] [Related]
26. Clinical and MRI outcome of cervical spine lesions in children with juvenile idiopathic arthritis treated with anti-TNFα drugs early in disease course. Ključevšek D; Emeršič N; Toplak N; Avčin T Pediatr Rheumatol Online J; 2017 May; 15(1):38. PubMed ID: 28506237 [TBL] [Abstract][Full Text] [Related]
27. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Nordal E; Zak M; Aalto K; Berntson L; Fasth A; Herlin T; Lahdenne P; Nielsen S; Straume B; Rygg M; Arthritis Rheum; 2011 Sep; 63(9):2809-18. PubMed ID: 21560116 [TBL] [Abstract][Full Text] [Related]
28. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Simonini G; Giani T; Stagi S; de Martino M; Falcini F Rheumatology (Oxford); 2005 Jun; 44(6):777-80. PubMed ID: 15741191 [TBL] [Abstract][Full Text] [Related]
29. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM; Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571 [TBL] [Abstract][Full Text] [Related]
30. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Chon Y; Zhang N; Baumgartner SW Arthritis Rheum; 2010 Nov; 62(11):3259-64. PubMed ID: 20669280 [TBL] [Abstract][Full Text] [Related]
31. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. Briot K; Gossec L; Kolta S; Dougados M; Roux C J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782 [TBL] [Abstract][Full Text] [Related]
32. TNF-α gene polymorphisms and juvenile idiopathic arthritis: Influence on disease outcome and therapeutic response. Scardapane A; Ferrante R; Nozzi M; Savino A; Antonucci I; Dadorante V; Balsamo M; Stuppia L; Chiarelli F; Breda L Semin Arthritis Rheum; 2015 Aug; 45(1):35-41. PubMed ID: 25837015 [TBL] [Abstract][Full Text] [Related]
33. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register. Anink J; Otten MH; Prince FH; Hoppenreijs EP; Wulffraat NM; Swart JF; ten Cate R; van Rossum MA; van den Berg JM; Dolman KM; Koopman-Keemink Y; Armbrust W; Kamphuis S; van Pelt PA; Gorter SL; van Suijlekom-Smit LW Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169 [TBL] [Abstract][Full Text] [Related]
34. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001 [TBL] [Abstract][Full Text] [Related]
35. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Hinze CH; Foell D; Johnson AL; Spalding SJ; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Mehta J; Ting TV; Verbsky JW; Eberhard AB; Huang B; Giannini EH; Lovell DJ Arthritis Rheumatol; 2019 Mar; 71(3):451-459. PubMed ID: 30225949 [TBL] [Abstract][Full Text] [Related]
36. Disease course, outcome, and predictors of outcome in a population-based juvenile chronic arthritis cohort followed for 17 years. Bertilsson L; Andersson-Gäre B; Fasth A; Petersson IF; Forsblad-D'elia H J Rheumatol; 2013 May; 40(5):715-24. PubMed ID: 23418376 [TBL] [Abstract][Full Text] [Related]
37. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients. Spîrchez M; Samaşca G; Iancu M; Bolba C; Miu N Clin Lab; 2012; 58(3-4):253-60. PubMed ID: 22582498 [TBL] [Abstract][Full Text] [Related]
38. 90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis. Cecamore C; Marsili M; Salvatore R; Troiani R; D'Egidio M; Tinari N; Pelliccia P; Chiarelli F; Marcovecchio ML; Breda L Mod Rheumatol; 2018 Jul; 28(4):637-641. PubMed ID: 29157059 [TBL] [Abstract][Full Text] [Related]
39. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept. Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081 [TBL] [Abstract][Full Text] [Related]
40. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. Stoof SP; Heijstek MW; Sijssens KM; van der Klis F; Sanders EA; Teunis PF; Wulffraat NM; Berbers GA Ann Rheum Dis; 2014 Apr; 73(4):728-34. PubMed ID: 23505231 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]